GlobeNewswire

Call for Speakers Now Open for Percona Live Open Source Database Conference Europe 2018

Dela

Annual Conference Moves to Frankfurt; Accepting Speaker Proposals Through August 10, 2018

RALEIGH, N.C., July 10, 2018 (GLOBE NEWSWIRE) -- Percona, the company that delivers enterprise-class MySQL®, MariaDB and MongoDB®, PostgreSQL and other open source database solutions and services, today announced the Call for Speakers for Percona Live Open Source Database Conference Europe 2018 is open and accepting proposals through August 10, 2018. The Percona Live Open Source Database Conference Europe 2018 will take place November 5-7, 2018, at the Radisson Blu Frankfurt hotel in Frankfurt, Germany. Sponsorship opportunities are now available.

The Percona Live Open Source Database Conference Europe 2018 is the premier open source database event. The theme for the upcoming conference is "Connect. Accelerate. Innovate." Percona Live conferences provide the open source database community with an opportunity to discover and discuss the latest open source trends, technologies and innovations. The conference includes the best and brightest innovators and influencers in the open source database industry.

The 2018 conference will introduce a new "business" track, which will take place on Monday, November 5. The new track will be targeted to business leaders who are exploring the use of open source and are interested in learning more about its benefits as well as common business pains and how these have been addressed through use cases and case studies.

The conference committee is looking for proposals that cover the many aspects of using, deploying and managing open source databases, including:

  • Security - All of us have experienced security challenges. Whether they are initiated by legislature (GDPR), bugs (Meltdown/Spectre), experience (external attacks) or due diligence (planning for the worst), when do you have 'enough' security? Are you finding that security requirements are preventing your from being agile?
  • Serverless, Cloud or On Premise - The technology landscape is no longer a simple one and mixing infrastructures has almost become the norm. Are you designing data architectures for the new landscape, and eager to share your experience? Have microservices become an important part of your plans?
  • MySQL - Do you have an opinion on what is new and exciting in MySQL? With the release of MySQL 8.0, are you using the latest features? How and why? Are they helping you solve any business issues, or making deployment of applications and websites easier, faster or more efficient? Did the new release get you to change to MySQL? What do you see as the biggest impact of the MySQL 8.0 release? Do you use MySQL in conjunction with other databases in your environment?
  • MongoDB - How has the 3.6 release improved your experience in application development or time-to-market? How are the new features making your database environment better? What is it about MongoDB 4.0 that excites you? What are your experiences with Atlas? Have you moved to it, and has it lived up to its promises? Do you use MongoDB in conjunction with other databases in your environment?
  • PostgreSQL - Why do you use PostgreSQL as opposed to other SQL options? Have you done a comparison or benchmark of PostgreSQL vs. other types of databases related to your tasks? Why and what were the results? How does PostgreSQL help you with application performance or deployment? How do you use PostgreSQL in conjunction with other databases in your environment?
  • SQL, NewSQL, NoSQL - It's become a perennial question without an easy answer. How do databases compare, how do you choose the right technology for the job, how do you trade off between features and their benefits in comparing databases? If you have ever tried a hybrid database approach in a single application, how did that work out? How nicely does MongoDB play with MySQL in the real world? Do you have anything to say about using SQL with NoSQL databases?
  • High Availability - What choices are you making to ensure high availability? How do you find the balance between redundancy and cost? Are you using hot backups, and if so, what happened when you needed to rollback on them? 
  • Scalability - When did you recognize you needed to address data scale? Did your data growth take you by surprise or were you always in control? Did it take a degradation in performance to get your management to sit up and take notice? How do you plan for scale if you can't predict demand?
  • What the Future Holds - What do you see as the "next big thing"? What new and exciting features are going to be released? What's in your next release? What new technologies will affect the database landscape? AI? Machine learning? Blockchain databases? Let us know about innovations you see on the way.

Breakout sessions are 50 minutes in length, including a Q&A. Tutorial sessions are three or six hours in length, focused on an immediate and practical application of in-depth knowledge, and targeted at a level between a training class and a conference breakout session. Tutorial speakers should assume that attendees will have laptops to work through detailed and potentially hands-on presentations. Lightning Talks are five-minute presentations focusing on one key point that interests the open source community: technical, lighthearted or entertaining talks on new ideas, a successful project, a cautionary story, a quick tip or demonstration.

Selected speakers will receive a complimentary full conference pass.

Sponsorships
Sponsorship opportunities for Percona Live Open Source Database Conference Europe 2018 are available and offer the opportunity to interact with hundreds of DBAs, sysadmins, developers, CTOs, CEOs, business managers, technology evangelists, solution vendors, and entrepreneurs who typically attend the event. Contact live@percona.com for sponsorship details.

Percona Live Conferences

What:               Percona Live Open Source Database Conference Europe 2018 
Where:            Radisson Blu Frankfurt, Franklinstraße 65, Frankfurt, Germany
When:              November 5-7, 2018
Call for Papers Deadline:  August 10, 2018

Company Information

Press Contact
Brigit Valencia
For Percona
(360) 597-4516
bdbvalencia@gmail.com

About Percona

With more than 3,000 customers worldwide, Percona is the only company that delivers enterprise-class solutions for both MySQL® MariaDB®, MongoDB® and PostgreSQL across traditional and cloud-based platforms. The company provides SoftwareSupport,  Consulting, and Managed Services to large, well-known global brands such as Cisco Systems, Time Warner Cable, Alcatel-Lucent, Rent the Runway and the BBC, as well as smaller enterprises looking to maximize application performance while streamlining database efficiencies. Well established as thought leaders, Percona experts author content for the Percona Database Performance Blog and the Percona Live Open Source Database Conferences draw attendees and expert technical speakers from around the world. For more information, visit www.percona.com.

Percona® is a registered trademark of Percona LLC. All other registered and unregistered trademarks in this document are the sole property of their respective owners.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Percona via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum